{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T20:31:51Z","timestamp":1777408311464,"version":"3.51.4"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,12]]},"DOI":"10.7759\/cureus.46893","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T11:18:21Z","timestamp":1697109501000},"source":"Crossref","is-referenced-by-count":6,"title":["Advancements in the Management of Severe Community-Acquired Pneumonia: A Comprehensive Narrative Review"],"prefix":"10.7759","author":[{"given":"Don","family":"Davis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jainisha","family":"Thadhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vatsalya","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reem","family":"Nausheem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristhian R","family":"Vallejo-Zambrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bushra","family":"Mohammad Arifuddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mujahaith","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan J","family":"Carson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fnu","family":"Kanwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lavanya","family":"Nagarajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00259-0","article-title":"Pneumonia","volume":"7","author":"Torres A","year":"2021","unstructured":"Torres A, Cilloniz C, Niederman MS, Men\u00e9ndez R, Chalmers JD, Wunderink RG, van der Poll T. Pneumonia. Nat Rev Dis Primers. 2021, 7:25. 10.1038\/s41572-021-00259-0","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.03.015","article-title":"Declining mortality among hospitalized patients with community-acquired pneumonia","volume":"22","author":"Simonetti AF","year":"2016","unstructured":"Simonetti AF, Garcia-Vidal C, Viasus D, Garc\u00eda-Somoza D, Dorca J, Gudiol F, Carratal\u00e0 J. Declining mortality among hospitalized patients with community-acquired pneumonia. Clin Microbiol Infect. 2016, 22:567.e1-7. 10.1016\/j.cmi.2016.03.015","journal-title":"Clin Microbiol Infect"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191721","article-title":"Severe community-acquired pneumonia: characteristics and prognostic factors in ventilated and non-ventilated patients","volume":"13","author":"Ferrer M","year":"2018","unstructured":"Ferrer M, Travierso C, Cilloniz C, et al.. Severe community-acquired pneumonia: characteristics and prognostic factors in ventilated and non-ventilated patients. PLoS One. 2018, 13:e0191721. 10.1371\/journal.pone.0191721","journal-title":"PLoS One"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44 Suppl 2","author":"Mandell LA","year":"2007","unstructured":"Mandell LA, Wunderink RG, Anzueto A, et al.. Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007, 44 Suppl 2:S27-72. 10.1086\/511159","journal-title":"Clin Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3182a66b9b","article-title":"Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis","volume":"42","author":"Sligl WI","year":"2014","unstructured":"Sligl WI, Asadi L, Eurich DT, Tjosvold L, Marrie TJ, Majumdar SR. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med. 2014, 42:420-32. 10.1097\/CCM.0b013e3182a66b9b","journal-title":"Crit Care Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1086\/367541","article-title":"Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia","volume":"36","author":"Mart\u00ednez JA","year":"2003","unstructured":"Mart\u00ednez JA, Horcajada JP, Almela M, et al.. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2003, 36:389-95. 10.1086\/367541","journal-title":"Clin Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010406.pub2","article-title":"Corticosteroids as adjunctive therapy in the treatment of influenza","volume":"3","author":"Rodrigo C","year":"2016","unstructured":"Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev. 2016, 3:CD010406. 10.1002\/14651858.CD010406.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy600","article-title":"Delafloxacin: a new anti-methicillin-resistant Staphylococcus aureus fluoroquinolone","volume":"68","author":"Saravolatz LD","year":"2019","unstructured":"Saravolatz LD, Stein GE. Delafloxacin: a new anti-methicillin-resistant Staphylococcus aureus fluoroquinolone. Clin Infect Dis. 2019, 68:1058-62. 10.1093\/cid\/ciy600","journal-title":"Clin Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets R","year":"2019","unstructured":"Stets R, Popescu M, Gonong JR, et al.. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019, 380:517-27. 10.1056\/NEJMoa1800201","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2166","article-title":"Lefamulin: review of a promising novel pleuromutilin antibiotic","volume":"38","author":"Veve MP","year":"2018","unstructured":"Veve MP, Wagner JL. Lefamulin: review of a promising novel pleuromutilin antibiotic. Pharmacotherapy. 2018, 38:935-46. 10.1002\/phar.2166","journal-title":"Pharmacotherapy"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2009.04.003","article-title":"Severe community-acquired pneumonia","volume":"23","author":"Restrepo MI","year":"2009","unstructured":"Restrepo MI, Anzueto A. Severe community-acquired pneumonia. Infect Dis Clin North Am. 2009, 23:503-20. 10.1016\/j.idc.2009.04.003","journal-title":"Infect Dis Clin North Am"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.9.1059","article-title":"Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study","volume":"162","author":"Mortensen EM","year":"2002","unstructured":"Mortensen EM, Coley CM, Singer DE, Marrie TJ, Obrosky DS, Kapoor WN, Fine MJ. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med. 2002, 162:1059-64. 10.1001\/archinte.162.9.1059","journal-title":"Arch Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jped.2019.08.003","article-title":"Community-acquired pneumonia among children: the latest evidence for an updated management","volume":"96 Suppl 1","author":"Nascimento-Carvalho CM","year":"2020","unstructured":"Nascimento-Carvalho CM. Community-acquired pneumonia among children: the latest evidence for an updated management. J Pediatr (Rio J). 2020, 96 Suppl 1:29-38. 10.1016\/j.jped.2019.08.003","journal-title":"J Pediatr (Rio J)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2035194","article-title":"Aetiology of severe community acquired pneumonia in adults identified by combined detection methods: a multi-centre prospective study in China","volume":"11","author":"Qu J","year":"2022","unstructured":"Qu J, Zhang J, Chen Y, et al.. Aetiology of severe community acquired pneumonia in adults identified by combined detection methods: a multi-centre prospective study in China. Emerg Microbes Infect. 2022, 11:556-66. 10.1080\/22221751.2022.2035194","journal-title":"Emerg Microbes Infect"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201112-2240OC","article-title":"Viral infection in patients with severe pneumonia requiring intensive care unit admission","volume":"186","author":"Choi SH","year":"2012","unstructured":"Choi SH, Hong SB, Ko GB, et al.. Viral infection in patients with severe pneumonia requiring intensive care unit admission. Am J Respir Crit Care Med. 2012, 186:325-32. 10.1164\/rccm.201112-2240OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-06323-9","article-title":"Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study","volume":"47","author":"Rouz\u00e9 A","year":"2021","unstructured":"Rouz\u00e9 A, Martin-Loeches I, Povoa P, et al.. Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study. Intensive Care Med. 2021, 47:188-98. 10.1007\/s00134-020-06323-9","journal-title":"Intensive Care Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(22)00390-1","article-title":"Efficacy of SARS-CoV-2 vaccines and the dose-response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials","volume":"4","author":"Yang ZR","year":"2023","unstructured":"Yang ZR, Jiang YW, Li FX, et al.. Efficacy of SARS-CoV-2 vaccines and the dose-response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials. Lancet Microbe. 2023, 4:e236-46. 10.1016\/S2666-5247(22)00390-1","journal-title":"Lancet Microbe"},{"key":"ref18","article-title":"Overview of community-acquired pneumonia in adults","author":"Ramirez JA","year":"2023","unstructured":"Ramirez JA. Overview of community-acquired pneumonia in adults. UpToDate. Ted. W. Post (ed): UpToDate, Waltham, MA; 2023."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.21037\/arh.2017.12.03","article-title":"Epidemiology, pathophysiology, and microbiology of community-acquired pneumonia","volume":"2","author":"Cill\u00f3niz C","year":"2018","unstructured":"Cill\u00f3niz C, Cardozo C, Garc\u00eda-Vidal C. Epidemiology, pathophysiology, and microbiology of community-acquired pneumonia. Ann Res Hosp. 2018, 2:1. 10.21037\/arh.2017.12.03","journal-title":"Ann Res Hosp"},{"key":"ref20","article-title":"Community-Acquired Pneumonia","author":"Regunath H","year":"2023","unstructured":"Regunath H, Oba Y. Community-Acquired Pneumonia. In: StatPearls [Internet] (ed): StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-7091-0715-7_34","article-title":"Community-acquired pneumonia","author":"Sialer S","year":"2014","unstructured":"Sialer S, Difrancesco LF, Fabregas TF, Torres A. Community-acquired pneumonia. Metabolism of Human Diseases. 2014, 227-31. 10.1007\/978-3-7091-0715-7_34","journal-title":"Metabolism of Human Diseases"},{"key":"ref22","unstructured":"Community Acquired Pneumonia -Infectious Disease and Antimicrobial Agents. Accessed. August 1, 2023: http:\/\/www.antimicrobe.org\/e55.asp."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-5326-0","article-title":"Mucosal Immunology of Acute Bacterial Pneumonia","author":"Prince A","year":"2012","unstructured":"Prince A. Mucosal Immunology of Acute Bacterial Pneumonia. Springer, New York, NY; 2012. 10.1007\/978-1-4614-5326-0"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-021014-071937","article-title":"Dynamics of lung defense in pneumonia: resistance, resilience, and remodeling","volume":"77","author":"Quinton LJ","year":"2015","unstructured":"Quinton LJ, Mizgerd JP. Dynamics of lung defense in pneumonia: resistance, resilience, and remodeling. Annu Rev Physiol. 2015, 77:407-30. 10.1146\/annurev-physiol-021014-071937","journal-title":"Annu Rev Physiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00107-18","article-title":"Host-pathogen interactions in Gram-positive bacterial pneumonia","volume":"32","author":"Grousd JA","year":"2019","unstructured":"Grousd JA, Rich HE, Alcorn JF. Host-pathogen interactions in Gram-positive bacterial pneumonia. Clin Microbiol Rev. 2019, 32:e00107-18. 10.1128\/CMR.00107-18","journal-title":"Clin Microbiol Rev"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1172\/JCI95823","article-title":"Disruption of staphylococcal aggregation protects against lethal lung injury","volume":"128","author":"Hook JL","year":"2018","unstructured":"Hook JL, Islam MN, Parker D, Prince AS, Bhattacharya S, Bhattacharya J. Disruption of staphylococcal aggregation protects against lethal lung injury. J Clin Invest. 2018, 128:1074-86. 10.1172\/JCI95823","journal-title":"J Clin Invest"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.3.9812047","article-title":"Influenza virus inhibits lysozyme secretion by sputum neutrophils in subjects with chronic bronchial sepsis","volume":"161","author":"Pang G","year":"2000","unstructured":"Pang G, Clancy R, Cong M, Ortega M, Zhigang R, Reeves G. Influenza virus inhibits lysozyme secretion by sputum neutrophils in subjects with chronic bronchial sepsis. Am J Respir Crit Care Med. 2000, 161:718-22. 10.1164\/ajrccm.161.3.9812047","journal-title":"Am J Respir Crit Care Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163889","article-title":"Viral inhibition of bacterial phagocytosis by human macrophages: redundant role of CD36","volume":"11","author":"Cooper GE","year":"2016","unstructured":"Cooper GE, Pounce ZC, Wallington JC, et al.. Viral inhibition of bacterial phagocytosis by human macrophages: redundant role of CD36. PLoS One. 2016, 11:e0163889. 10.1371\/journal.pone.0163889","journal-title":"PLoS One"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1462-5822.2012.01772.x","article-title":"Cross-talk between Staphylococcus aureus leukocidins-intoxicated macrophages and lung epithelial cells triggers chemokine secretion in an inflammasome-dependent manner","volume":"14","author":"Perret M","year":"2012","unstructured":"Perret M, Badiou C, Lina G, et al.. Cross-talk between Staphylococcus aureus leukocidins-intoxicated macrophages and lung epithelial cells triggers chemokine secretion in an inflammasome-dependent manner. Cell Microbiol. 2012, 14:1019-36. 10.1111\/j.1462-5822.2012.01772.x","journal-title":"Cell Microbiol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/acem.13965","article-title":"Accuracy of signs and symptoms for the diagnosis of community-acquired pneumonia: a meta-analysis","volume":"27","author":"Ebell MH","year":"2020","unstructured":"Ebell MH, Chupp H, Cai X, Bentivegna M, Kearney M. Accuracy of signs and symptoms for the diagnosis of community-acquired pneumonia: a meta-analysis. Acad Emerg Med. 2020, 27:541-53. 10.1111\/acem.13965","journal-title":"Acad Emerg Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03550170070035","article-title":"Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination","volume":"278","author":"Metlay JP","year":"1997","unstructured":"Metlay JP, Kapoor WN, Fine MJ. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA. 1997, 278:1440-5. 10.1001\/jama.1997.03550170070035","journal-title":"JAMA"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2005.08.011","article-title":"Diagnosing pneumonia by medical history and physical examination","volume":"46","author":"Rosh AJ","year":"2005","unstructured":"Rosh AJ, Newman DH. Diagnosing pneumonia by medical history and physical examination. Ann Emerg Med. 2005, 46:465-7. 10.1016\/j.annemergmed.2005.08.011","journal-title":"Ann Emerg Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay JP","year":"2019","unstructured":"Metlay JP, Waterer GW, Long AC, et al.. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019, 200:e45-67. 10.1164\/rccm.201908-1581ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-2-200301210-00012","article-title":"Testing strategies in the initial management of patients with community-acquired pneumonia","volume":"138","author":"Metlay JP","year":"2003","unstructured":"Metlay JP, Fine MJ. Testing strategies in the initial management of patients with community-acquired pneumonia. Ann Intern Med. 2003, 138:109-18. 10.7326\/0003-4819-138-2-200301210-00012","journal-title":"Ann Intern Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.06.026","article-title":"Community-acquired pneumonia in the emergency department: an algorithm to facilitate diagnosis and guide chest CT scan indication","volume":"26","author":"Loubet P","year":"2020","unstructured":"Loubet P, Tubiana S, Claessens YE, et al.. Community-acquired pneumonia in the emergency department: an algorithm to facilitate diagnosis and guide chest CT scan indication. Clin Microbiol Infect. 2020, 26:382.e1-7. 10.1016\/j.cmi.2019.06.026","journal-title":"Clin Microbiol Infect"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.07.035","article-title":"Community-acquired pneumonia visualized on CT scans but not chest radiographs: pathogens, severity, and clinical outcomes","volume":"153","author":"Upchurch CP","year":"2018","unstructured":"Upchurch CP, Grijalva CG, Wunderink RG, et al.. Community-acquired pneumonia visualized on CT scans but not chest radiographs: pathogens, severity, and clinical outcomes. Chest. 2018, 153:601-10. 10.1016\/j.chest.2017.07.035","journal-title":"Chest"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201501-0017OC","article-title":"Early chest computed tomography scan to assist diagnosis and guide treatment decision for suspected community-acquired pneumonia","volume":"192","author":"Claessens YE","year":"2015","unstructured":"Claessens YE, Debray MP, Tubach F, et al.. Early chest computed tomography scan to assist diagnosis and guide treatment decision for suspected community-acquired pneumonia. Am J Respir Crit Care Med. 2015, 192:974-82. 10.1164\/rccm.201501-0017OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000567","article-title":"Computed tomography scan contribution to the diagnosis of community-acquired pneumonia","volume":"25","author":"Garin N","year":"2019","unstructured":"Garin N, Marti C, Scheffler M, Stirnemann J, Prendki V. Computed tomography scan contribution to the diagnosis of community-acquired pneumonia. Curr Opin Pulm Med. 2019, 25:242-8. 10.1097\/MCP.0000000000000567","journal-title":"Curr Opin Pulm Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03550230056037","article-title":"Quality of care, process, and outcomes in elderly patients with pneumonia","volume":"278","author":"Meehan TP","year":"1997","unstructured":"Meehan TP, Fine MJ, Krumholz HM, et al.. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA. 1997, 278:2080-4. 10.1001\/jama.1997.03550230056037","journal-title":"JAMA"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-005-4096-2","article-title":"Diagnostic and prognostic values of admission procalcitonin levels in community-acquired pneumonia in an intensive care unit","volume":"33","author":"Boussekey N","year":"2005","unstructured":"Boussekey N, Leroy O, Georges H, Devos P, d'Escrivan T, Guery B. Diagnostic and prognostic values of admission procalcitonin levels in community-acquired pneumonia in an intensive care unit. Infection. 2005, 33:257-63. 10.1007\/s15010-005-4096-2","journal-title":"Infection"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1002\/art.11025","article-title":"C-reactive protein as a regulator of autoimmunity and inflammation","volume":"48","author":"Du Clos TW","year":"2003","unstructured":"Du Clos TW. C-reactive protein as a regulator of autoimmunity and inflammation. Arthritis Rheum. 2003, 48:1475-7. 10.1002\/art.11025","journal-title":"Arthritis Rheum"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1378\/chest.125.4.1335","article-title":"Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia","volume":"125","author":"Almirall J","year":"2004","unstructured":"Almirall J, Bol\u00edbar I, Toran P, Pera G, Boquet X, Balanz\u00f3 X, Sauca G. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest. 2004, 125:1335-42. 10.1378\/chest.125.4.1335","journal-title":"Chest"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2006.11271","article-title":"Diagnostic value of signs, symptoms and laboratory values in lower respiratory tract infection","volume":"136","author":"Stolz D","year":"2006","unstructured":"Stolz D, Christ-Crain M, Gencay MM, Bingisser R, Huber PR, M\u00fcller B, Tamm M. Diagnostic value of signs, symptoms and laboratory values in lower respiratory tract infection. Swiss Med Wkly. 2006, 136:434-40. 10.4414\/smw.2006.11271","journal-title":"Swiss Med Wkly"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2020.02.182","article-title":"Diagnostic markers for community-acquired pneumonia","volume":"8","author":"Ito A","year":"2020","unstructured":"Ito A, Ishida T. Diagnostic markers for community-acquired pneumonia. Ann Transl Med. 2020, 8:609. 10.21037\/atm.2020.02.182","journal-title":"Ann Transl Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9610(98)00204-9","article-title":"Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer","volume":"176","author":"Nozoe T","year":"1998","unstructured":"Nozoe T, Matsumata T, Kitamura M, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg. 1998, 176:335-8. 10.1016\/s0002-9610(98)00204-9","journal-title":"Am J Surg"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/s0049-0172(05)80003-4","article-title":"The value of C-reactive protein measurement in rheumatoid arthritis","volume":"24","author":"Otterness IG","year":"1994","unstructured":"Otterness IG. The value of C-reactive protein measurement in rheumatoid arthritis. Semin Arthritis Rheum. 1994, 24:91-104. 10.1016\/s0049-0172(05)80003-4","journal-title":"Semin Arthritis Rheum"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2020.10.024","article-title":"Clinical policy: Critical issues in the management of adult patients presenting to the emergency department with community-acquired pneumonia","volume":"77","author":"Smith MD","year":"2021","unstructured":"Smith MD, Fee C, Mace SE, Maughan B, Perkins JC Jr, Kaji A, Wolf SJ. Clinical policy: Critical issues in the management of adult patients presenting to the emergency department with community-acquired pneumonia. Ann Emerg Med. 2021, 77:e1-e57. 10.1016\/j.annemergmed.2020.10.024","journal-title":"Ann Emerg Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.01.006","article-title":"Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia","volume":"118","author":"Aujesky D","year":"2005","unstructured":"Aujesky D, Auble TE, Yealy DM, et al.. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med. 2005, 118:384-92. 10.1016\/j.amjmed.2005.01.006","journal-title":"Am J Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.12.1350","article-title":"Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial","volume":"158","author":"Atlas SJ","year":"1998","unstructured":"Atlas SJ, Benzer TI, Borowsky LH, et al.. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. Arch Intern Med. 1998, 158:1350-6. 10.1001\/archinte.158.12.1350","journal-title":"Arch Intern Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2010.04.018","article-title":"The effects of incorporating a pneumonia severity index into the admission protocol for community-acquired pneumonia","volume":"42","author":"Jo S","year":"2012","unstructured":"Jo S, Kim K, Jung K, Rhee JE, Cho IS, Lee CC, Singer AJ. The effects of incorporating a pneumonia severity index into the admission protocol for community-acquired pneumonia. J Emerg Med. 2012, 42:133-8. 10.1016\/j.jemermed.2010.04.018","journal-title":"J Emerg Med"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.arbres.2012.12.008","article-title":"Improved management of community-acquired pneumonia in the emergency department","volume":"49","author":"Juli\u00e1n-Jim\u00e9nez A","year":"2013","unstructured":"Juli\u00e1n-Jim\u00e9nez A, Palomo de los Reyes MJ, Parejo Miguez R, La\u00edn-Ter\u00e9s N, Cuena-Boy R, Lozano-Anc\u00edn A. Improved management of community-acquired pneumonia in the emergency department. Arch Bronconeumol. 2013, 49:230-40. 10.1016\/j.arbres.2012.12.008","journal-title":"Arch Bronconeumol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1086\/509331","article-title":"Routine use of the Pneumonia Severity Index for guiding the site-of-treatment decision of patients with pneumonia in the emergency department: a multicenter, prospective, observational, controlled cohort study","volume":"44","author":"Renaud B","year":"2007","unstructured":"Renaud B, Coma E, Labarere J, et al.. Routine use of the Pneumonia Severity Index for guiding the site-of-treatment decision of patients with pneumonia in the emergency department: a multicenter, prospective, observational, controlled cohort study. Clin Infect Dis. 2007, 44:41-9. 10.1086\/509331","journal-title":"Clin Infect Dis"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201904-0841OC","article-title":"Physiological comparison of high-flow nasal cannula and helmet noninvasive ventilation in acute hypoxemic respiratory failure","volume":"201","author":"Grieco DL","year":"2020","unstructured":"Grieco DL, Menga LS, Raggi V, et al.. Physiological comparison of high-flow nasal cannula and helmet noninvasive ventilation in acute hypoxemic respiratory failure. Am J Respir Crit Care Med. 2020, 201:303-12. 10.1164\/rccm.201904-0841OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503326","article-title":"High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure","volume":"372","author":"Frat JP","year":"2015","unstructured":"Frat JP, Thille AW, Mercat A, et al.. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015, 372:2185-96. 10.1056\/NEJMoa1503326","journal-title":"N Engl J Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1186\/cc10597","article-title":"Bench-to-bedside review: immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective","volume":"16","author":"Shankar-Hari M","year":"2012","unstructured":"Shankar-Hari M, Spencer J, Sewell WA, Rowan KM, Singer M. Bench-to-bedside review: immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective. Crit Care. 2012, 16:206. 10.1186\/cc10597","journal-title":"Crit Care"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2013.09.005","article-title":"Serum immunoglobulins in the infected and convalescent phases in community-acquired pneumonia","volume":"107","author":"de la Torre MC","year":"2013","unstructured":"de la Torre MC, Bol\u00edbar I, Vendrell M, et al.. Serum immunoglobulins in the infected and convalescent phases in community-acquired pneumonia. Respir Med. 2013, 107:2038-45. 10.1016\/j.rmed.2013.09.005","journal-title":"Respir Med"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2016.05.005","article-title":"IgG2 as an independent risk factor for mortality in patients with community-acquired pneumonia","volume":"35","author":"de la Torre MC","year":"2016","unstructured":"de la Torre MC, Palomera E, Serra-Prat M, G\u00fcell E, Y\u00e9benes JC, Bermejo-Mart\u00edn JF, Almirall J. IgG2 as an independent risk factor for mortality in patients with community-acquired pneumonia. J Crit Care. 2016, 35:115-9. 10.1016\/j.jcrc.2016.05.005","journal-title":"J Crit Care"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001090.pub2","article-title":"Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock","volume":"2013","author":"Alejandria MM","year":"2013","unstructured":"Alejandria MM, Lansang MA, Dans LF, Mantaring JB 3rd. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev. 2013, 2013:CD001090. 10.1002\/14651858.CD001090.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2011.05.012","article-title":"Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: a retrospective analysis","volume":"27","author":"Berlot G","year":"2012","unstructured":"Berlot G, Vassallo MC, Busetto N, et al.. Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: a retrospective analysis. J Crit Care. 2012, 27:167-71. 10.1016\/j.jcrc.2011.05.012","journal-title":"J Crit Care"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2015.03.008","article-title":"Concept for a study design in patients with severe community-acquired pneumonia: a randomised controlled trial with a novel IGM-enriched immunoglobulin preparation - The CIGMA study","volume":"109","author":"Welte T","year":"2015","unstructured":"Welte T, Dellinger RP, Ebelt H, et al.. Concept for a study design in patients with severe community-acquired pneumonia: a randomised controlled trial with a novel IGM-enriched immunoglobulin preparation - The CIGMA study. Respir Med. 2015, 109:758-67. 10.1016\/j.rmed.2015.03.008","journal-title":"Respir Med"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.medin.2016.05.008","article-title":"Impact on patient outcome of emergency department length of stay prior to ICU admission","volume":"41","author":"Garc\u00eda-Gigorro R","year":"2017","unstructured":"Garc\u00eda-Gigorro R, de la Cruz Vigo F, Andr\u00e9s-Esteban EM, Chac\u00f3n-Alves S, Morales Varas G, S\u00e1nchez-Izquierdo JA, Montejo Gonz\u00e1lez JC. Impact on patient outcome of emergency department length of stay prior to ICU admission. Med Intensiva. 2017, 41:201-8. 10.1016\/j.medin.2016.05.008","journal-title":"Med Intensiva"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-023-07033-8","article-title":"ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of severe community-acquired pneumonia","volume":"49","author":"Martin-Loeches I","year":"2023","unstructured":"Martin-Loeches I, Torres A, Nagavci B, et al.. ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Med. 2023, 49:615-32. 10.1007\/s00134-023-07033-8","journal-title":"Intensive Care Med"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-015-1000-z","article-title":"Adequate antibiotic therapy prior to ICU admission in patients with severe sepsis and septic shock reduces hospital mortality","volume":"19","author":"Garnacho-Montero J","year":"2015","unstructured":"Garnacho-Montero J, Guti\u00e9rrez-Pizarraya A, Escoresca-Ortega A, Fern\u00e1ndez-Delgado E, L\u00f3pez-S\u00e1nchez JM. Adequate antibiotic therapy prior to ICU admission in patients with severe sepsis and septic shock reduces hospital mortality. Crit Care. 2015, 19:302. 10.1186\/s13054-015-1000-z","journal-title":"Crit Care"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2018.1512403","article-title":"Severe community-acquired pneumonia: current management and future therapeutic alternatives","volume":"16","author":"Garnacho-Montero J","year":"2018","unstructured":"Garnacho-Montero J, Barrero-Garc\u00eda I, G\u00f3mez-Prieto MG, Mart\u00edn-Loeches I. Severe community-acquired pneumonia: current management and future therapeutic alternatives. Expert Rev Anti Infect Ther. 2018, 16:667-77. 10.1080\/14787210.2018.1512403","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-1531","article-title":"Decrease in mortality in severe community-acquired pneumococcal pneumonia: impact of improving antibiotic strategies (2000-2013)","volume":"146","author":"Gattarello S","year":"2014","unstructured":"Gattarello S, Borgatta B, Sol\u00e9-Viol\u00e1n J, et al.. Decrease in mortality in severe community-acquired pneumococcal pneumonia: impact of improving antibiotic strategies (2000-2013). Chest. 2014, 146:22-31. 10.1378\/chest.13-1531","journal-title":"Chest"},{"key":"ref66","article-title":"Treatment of community-acquired pneumonia in adults in the outpatient setting","author":"File TM Jr","year":"2023","unstructured":"File TM Jr. Treatment of community-acquired pneumonia in adults in the outpatient setting. UpToDate. Ted. W. Post (ed): UpToDate, Waltham, MA; 2023."},{"key":"ref67","article-title":"Treatment of community-acquired pneumonia in adults who require hospitalization","author":"File TM Jr","year":"2023","unstructured":"File TM Jr. Treatment of community-acquired pneumonia in adults who require hospitalization. UpToDate. Ted. W. Post (ed): UpToDate, Waltham, MA; 2023."},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis414","article-title":"Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis","volume":"55","author":"Asadi L","year":"2012","unstructured":"Asadi L, Sligl WI, Eurich DT, Colmers IN, Tjosvold L, Marrie TJ, Majumdar SR. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis. 2012, 55:371-80. 10.1093\/cid\/cis414","journal-title":"Clin Infect Dis"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2018.01.003","article-title":"Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: a propensity score analysis","volume":"76","author":"De la Calle C","year":"2018","unstructured":"De la Calle C, Ternavasio-de la Vega HG, Morata L, et al.. Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: a propensity score analysis. J Infect. 2018, 76:342-7. 10.1016\/j.jinf.2018.01.003","journal-title":"J Infect"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1038\/srep14061","article-title":"Adjunctive systemic corticosteroids for hospitalized community-acquired pneumonia: systematic review and meta-analysis 2015 update","volume":"5","author":"Horita N","year":"2015","unstructured":"Horita N, Otsuka T, Haranaga S, et al.. Adjunctive systemic corticosteroids for hospitalized community-acquired pneumonia: systematic review and meta-analysis 2015 update. Sci Rep. 2015, 5:14061. 10.1038\/srep14061","journal-title":"Sci Rep"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010406.pub3","article-title":"Corticosteroids as adjunctive therapy in the treatment of influenza","volume":"2","author":"Lansbury L","year":"2019","unstructured":"Lansbury L, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev. 2019, 2:CD010406. 10.1002\/14651858.CD010406.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-019-05519-y","article-title":"Challenges in severe community-acquired pneumonia: a point-of-view review","volume":"45","author":"Torres A","year":"2019","unstructured":"Torres A, Chalmers JD, Dela Cruz CS, et al.. Challenges in severe community-acquired pneumonia: a point-of-view review. Intensive Care Med. 2019, 45:159-71. 10.1007\/s00134-019-05519-y","journal-title":"Intensive Care Med"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/j.anpedi.2019.01.009","article-title":"Oseltamivir for the treatment of influenza in children and adolescents","volume":"90","author":"Tagarro A","year":"2019","unstructured":"Tagarro A, Cruz-Ca\u00f1ete M, Otheo E, Launes C, Couceiro JA, P\u00e9rez C, Alfayate S. Oseltamivir for the treatment of influenza in children and adolescents. An Pediatr (Engl Ed). 2019, 90:317.e1-8. 10.1016\/j.anpedi.2019.01.009","journal-title":"An Pediatr (Engl Ed)"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.15468","article-title":"Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia: the leap 2 randomized clinical trial","volume":"322","author":"Alexander E","year":"2019","unstructured":"Alexander E, Goldberg L, Das AF, et al.. Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia: the leap 2 randomized clinical trial. JAMA. 2019, 322:1661-71. 10.1001\/jama.2019.15468","journal-title":"JAMA"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz090","article-title":"Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the Phase III Lefamulin Evaluation Against Pneumonia (Leap 1) Trial","volume":"69","author":"File TM","year":"2019","unstructured":"File TM, Goldberg L, Das A, et al.. Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the Phase III Lefamulin Evaluation Against Pneumonia (Leap 1) Trial. Clin Infect Dis. 2019, 69:1856-67. 10.1093\/cid\/ciz090","journal-title":"Clin Infect Dis"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz514","article-title":"A Phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (define-CABP)","volume":"7","author":"Horcajada JP","year":"2020","unstructured":"Horcajada JP, Salata RA, \u00c1lvarez-Sala R, et al.. A Phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (define-CABP). Open Forum Infect Dis. 2020, 7:ofz514. 10.1093\/ofid\/ofz514","journal-title":"Open Forum Infect Dis"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6434a4","article-title":"Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"64","author":"Kobayashi M","year":"2015","unstructured":"Kobayashi M, Bennett NM, Gierke R, Almendares O, Moore MR, Whitney CG, Pilishvili T. Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015, 64:944-7. 10.15585\/mmwr.mm6434a4","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref78","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Tomczyk S","year":"2014","unstructured":"Tomczyk S, Bennett NM, Stoecker C, et al.. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014, 63:822-5.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref79","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"61","author":"Centers for Disease Control and Prevention (CDC)","year":"2012","unstructured":"Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012, 61:816-9.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref80","unstructured":"Influenza Vaccination. A Summary for Clinicians | CDC. (2023). Accessed: August 16, 2023: https:\/\/www.cdc.gov\/flu\/professionals\/vaccination\/vax-summary.htm."},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201904-0839LE","article-title":"Bacteriophage therapy of ventilator-associated pneumonia and empyema caused by Pseudomonas aeruginosa","volume":"200","author":"Maddocks S","year":"2019","unstructured":"Maddocks S, Fabijan AP, Ho J, et al.. Bacteriophage therapy of ventilator-associated pneumonia and empyema caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2019, 200:1179-81. 10.1164\/rccm.201904-0839LE","journal-title":"Am J Respir Crit Care Med"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1561ED","article-title":"Turning the phage on treatment of antimicrobial-resistant pneumonia","volume":"200","author":"Wunderink RG","year":"2019","unstructured":"Wunderink RG. Turning the phage on treatment of antimicrobial-resistant pneumonia. Am J Respir Crit Care Med. 2019, 200:1081-2. 10.1164\/rccm.201908-1561ED","journal-title":"Am J Respir Crit Care Med"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-023-04561-z","article-title":"Efficacy and safety of adjunctive corticosteroids in the treatment of severe community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials","volume":"27","author":"Wu JY","year":"2023","unstructured":"Wu JY, Tsai YW, Hsu WH, et al.. Efficacy and safety of adjunctive corticosteroids in the treatment of severe community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials. Crit Care. 2023, 27:274. 10.1186\/s13054-023-04561-z","journal-title":"Crit Care"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1378\/chest.104.2.389","article-title":"Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study","volume":"104","author":"Marik P","year":"1993","unstructured":"Marik P, Kraus P, Sribante J, Havlik I, Lipman J, Johnson DW. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study. Chest. 1993, 104:389-92. 10.1378\/chest.104.2.389","journal-title":"Chest"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200406-808OC","article-title":"Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study","volume":"171","author":"Confalonieri M","year":"2005","unstructured":"Confalonieri M, Urbino R, Potena A, et al.. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2005, 171:242-8. 10.1164\/rccm.200406-808OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.4236\/pp.2011.22009","article-title":"Corticosteroids and ICU course of community acquired pneumonia in Egyptian settings","volume":"2","author":"Sabry NA","year":"2011","unstructured":"Sabry NA, Omar EE-D. Corticosteroids and ICU course of community acquired pneumonia in Egyptian settings. Pharmacol Pharm. 2011, 2:73-81. 10.4236\/pp.2011.22009","journal-title":"Pharmacol Pharm"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.88","article-title":"Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial","volume":"313","author":"Torres A","year":"2015","unstructured":"Torres A, Sibila O, Ferrer M, et al.. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015, 313:677-86. 10.1001\/jama.2015.88","journal-title":"JAMA"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-022-06684-3","article-title":"Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia","volume":"48","author":"Meduri GU","year":"2022","unstructured":"Meduri GU, Shih MC, Bridges L, et al.. Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia. Intensive Care Med. 2022, 48:1009-23. 10.1007\/s00134-022-06684-3","journal-title":"Intensive Care Med"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2215145","article-title":"Hydrocortisone in severe community-acquired pneumonia","volume":"388","author":"Dequin PF","year":"2023","unstructured":"Dequin PF, Meziani F, Quenot JP, et al.. Hydrocortisone in severe community-acquired pneumonia. N Engl J Med. 2023, 388:1931-41. 10.1056\/NEJMoa2215145","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/183137-advancements-in-the-management-of-severe-community-acquired-pneumonia-a-comprehensive-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:52:43Z","timestamp":1707508363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/183137-advancements-in-the-management-of-severe-community-acquired-pneumonia-a-comprehensive-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,12]]},"references-count":89,"URL":"https:\/\/doi.org\/10.7759\/cureus.46893","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,12]]}}}